Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson's disease

Hasriza Hashim, Shahrul Azmin, Hamizah Razlan, Nafisah Wan Yahya, Hui Jan Tan, M Rizal Abdul Manaf, Norlinah Mohamed Ibrahim, Hasriza Hashim, Shahrul Azmin, Hamizah Razlan, Nafisah Wan Yahya, Hui Jan Tan, M Rizal Abdul Manaf, Norlinah Mohamed Ibrahim

Abstract

Background: Previous studies have demonstrated a higher prevalence of Helicobacter pylori (H. pylori) infection in patients with Parkinson's disease (PD) compared to controls. H. pylori infection affects levodopa absorption and its eradication significantly improves clinical response to levodopa. Here, we studied the prevalence of H. pylori infection and its eradication effects among our PD patients.

Methods: A prospective study involving idiopathic PD patients on levodopa therapy. 13C-urea breath test (UBT) was used to detect H. pylori. UBT-positive patients were given standard eradication therapy and followed up at 6 and 12 weeks in an open label single arm design. Repeat UBT was performed at 12 weeks. The UPDRS, PD NMQ, PD NMSS and PDQ-39 were administered at baseline and post-eradication (6 and 12 weeks). Levodopa 'onset' time and ON-duration were recorded.

Results: Of 82 patients recruited, 27 (32.9%) had positive UBT. H. pylori-positive patients had significantly poorer total UPDRS (p = 0.005) and PDQ39 (p<0.0001) scores compared to H. pylori-negative patients. At 12 weeks post-eradication, the mean levodopa onset time shortened by 14 minutes (p = 0.011). The mean ON duration time increased by 56 minutes at week 6 (p = 0.041) and 38 minutes at week 12 (p = 0.035). The total UPDRS scores (p<0.0001), scores for parts II (p = 0.001), III (p<0.0001) and IV (p = 0.009) were significantly better. The total PDQ-39 scores (p = 0.001) and subdomains mobility (p = 0.002), ADL (p = 0.001), emotional well being (p = 0.026) and stigma (p = 0.034) significantly improved. The PD NMSQ did not show significant improvement.

Conclusions: H. pylori eradication improved levodopa onset time, ON duration, motor severity and quality of life parameters. Screening and eradication of H. pylori is inexpensive and should be recommended in PD patients, particularly those with erratic response to levodopa.

Trial registration: ClinicalTrials.gov NCT02112812.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Study Flow Chart.
Figure 1. Study Flow Chart.

References

    1. Strang RR (1965) The Association of Gastro-Duodenal Ulceration and Parkinson's Disease. The Medical journal of Australia 1: 842–843.
    1. Altschuler E (1996) Gastric Helicobacter pylori infection as a cause of idiopathic parkinson disease and non-arteric anterior optic ischemic neuropathy. Medical Hypotheses 47: 413–414.
    1. Bjarnason IT, Charlett A, Dobbs RJ, Dobbs SM, Ibrahim MA, et al. (2005) Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 2: response of facets of clinical idiopathic parkinsonism to Helicobacter pylori eradication. A randomized, double-blind, placebo-controlled efficacy study. Helicobacter 10: 276–287.
    1. Dobbs RJ, Dobbs SM, Weller C, Bjarnason IT, Oxlade NL, et al. (2005) Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 1: eradication of Helicobacter in the cachexia of idiopathic parkinsonism. Helicobacter 10: 267–275.
    1. Weller C, Charlett A, Oxlade NL, Dobbs SM, Dobbs RJ, et al. (2005) Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 3: predicted probability and gradients of severity of idiopathic parkinsonism based on H. pylori antibody profile. Helicobacter 10: 288–297.
    1. Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, et al. (1999) Association of circulating TNF-α and IL-6 with ageing and parkinsonism. Acta Neurologica Scandinavica 100: 34–41.
    1. Rees K, Stowe R, Patel S, Ives N, Breen K, et al.. (2011) Helicobacter pylori eradication for Parkinson's disease. Cochrane Database Syst Rev 11.
    1. Pierantozzi M, Pietroiusti A, Galante A, Sancessario G, Lunardi G, et al. (2001) Helicobacter pylori-induced reduction of acute levodopa absorption in Parkinson's disease patients. Ann Neurol 50: 686–687.
    1. Pierantozzi M, Pietroiusti A, Brusa L, Galati S, Stefani A, et al. (2006) Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology 66: 1824–1829.
    1. Nafisah W, Najman A, Hamizah R, Azmin S, Rabani R, et al. (2013) high prevalence of Helicobacter pylori infection in Malaysian Parkinson's disease patients. Journal of Parkinsonism and Restless Legs Syndrome 3: 63–67.
    1. Hamlet A, Thoreson AC, Nilsson O, Svennerholm AM, Olbe L, et al. (1999) Duodenal Helicobacter pylori infection differs in cagA genotype between asymptomatic subjjects and patients with duodenal ulcers. Gastroenterology 116: 259–268.
    1. Davies G, Simmonds NJ, Stevens TR, Sheaff MT, Banatvala N, et al. (1994) Helicobacter pylori stimulates antral mucosa reactive oxygen metabolite production in vivo . Gut 35: 179–185.
    1. Salim AS (1993) The relationship between Helicobacter pylori and oxygen derived free radicals in the mechanism of duodenal ulceration. Intern Med 32: 359–364.
    1. Kankkunen T, Huupponen I, Lahtinen K, Sundell M, Ekman K, et al. (2002) Improved stability and release control of of levodopa and metaraminol using ion-change fibers and transdermal iontophoresis. Eur J Pharm Sci 16: 273–280.
    1. Kalach N, Briet F, Raymond J, Benhamou PH, Barbet P, et al. (1998) The 13carbon urea breath test for the noninvasive detection of Helicobacter pylori in children: comparison with culture and determination of minimum analysis requirements. J Pediatr Gastroenterol Nutr 26: 291–296.
    1. Graham DY, Klein PD (2000) Accurate Diagnosis of Helicobacter pylori: 13C-Urea Breath Test. Gastroenterology Clinics of North America 29: 885–893.
    1. Zagari RM, Pozzato P, Martuzzi C, Fuccio L, Martinelli G, et al. (2005) 13C-Urea Breath Test to Assess Helicobacter pylori Bacterial Load. Helicobacter 10: 615–619.
    1. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon ATR, et al. (2012) Management of Helicobacter pylori infection—the Maastricht IV/Florence Consensus Report. Gut 61: 646–664.
    1. Asadi-Pooya AA, Dehghani SM, Petramfar P, Emami M, Mahmoodi M (2012) Helicobacter pylori infection in patients with epilepsy. Seizure 21: 21–23.
    1. Ozturk A, Ozturk CE, Ozdemirli B, Yucel M, Bahçebaşı T (2007) Helicobacter pylori infection in epileptic patients. Seizure 16: 147–152.
    1. Abdul Razak MR, Tan HJ, Razlan H, Ibrahim NM, Sutan R (2012) Prevalence of Helicobacter pylori infection in epilepsy patients in a teaching hospital in Malaysia. Neurology Asia 17: 3.
    1. Goetz CG, Wuu J, McDermott MP, Adler CH, Fahn S, et al. (2008) Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions. Movement Disorders 23: 690–699.
    1. Pierantozzi M, Pietroiusti A, Brusa L, Galati S, Stefani A, et al. (2006) Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology 66: 1824–1829.
    1. Narozanska E, Bialecka M, Adamiak-Giera U, Gawronska-Szklarz B, Soltan W, et al. (2014) Pharmacokinetics of Levodopa in Patients With Parkinson Disease and Motor Fluctuations Depending on the Presence of Helicobacter pylori Infection. Clinical Neuropharmacology 37: 96–99 10.1097/WNF.0000000000000037.
    1. Feldman M, Cryer B, Lee E (1998) Effects of Helicobacter pylori gastritis on gastric secretion in healthy human beings. Am J Physiol 274: G1011–1017.
    1. Beales ILP, Calam J (1998) Interleukin 1β and tumour necrosis factor α inhibit acid secretion in cultured rabbit parietalo cells by multiple pathways. Gut 42: 227–234.
    1. Takashima M, Furuta T, Hanai H, Sugimura H, Kaneko E (2001) Effects of Helicobacter pylori infection on gastric acid secretion and serum gastrin levels in Mongolian gerbils. Gut 48: 765–773.
    1. El-Omar EM (2001) The importance of interleukin 1β in Helicobacter pylori disease. Gut 48: 743–747.
    1. Annibale B, Di Giulio E, Caruana P, Lahner E, Capurso G, et al. (2002) The long-term effects of cure of Helicobacter pylori infection on patients with atrophic body gastritis. Alimentary pharmacology & therapeutics 16: 1723–1731.
    1. Thor P, Lorens K, Tabor S, Herman R, Konturek J, et al. (1996) Dysfunction in gastric myoelectric and motor activity in Helicobacter pylori positive gastritis patients with non-ulcer dyspesia. Journal of physiology and pharmacology: an official journal of the Polish Physiological Society 47: 469.
    1. Miyaji H, Azuma T, Ito S, Abe Y, Ono H, et al. (1999) The effect of Helicobacter pylori eradication therapy on gastric antral myoelectrical activity and gastric emptying in patients with non-ulcer dyspepsia. Alimentary Pharmacology and Therapeutics 13: 1303–1310.
    1. Doherty NC, Tobias A, Watson S, Atherton JC (2009) The Effect of the Human Gut-Signalling Hormone, Norepinephrine, on the Growth of the Gastric Pathogen Helicobacter pylori. Helicobacter 14: 223–230.
    1. Lee WY, Yoon WT, Shin HY, Jeon SH, Rhee PL (2008) Helicobacter pylori infection and motor fluctuation in patients with Parkinson's disease. Mov Disord 23: 1696–1700.
    1. Schrag A, Jahanshahi M, Quinn N (2000) What contributes to quality of life in patients with Parkinson's disease? Journal of Neurology, Neurosurgery & Psychiatry 69: 308–312.
    1. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F (2005) Impact of the motor complications of Parkinson's disease on the quality of life. Movement Disorders 20: 224–230.
    1. Sławek J, Derejko M, Lass P (2005) Factors affecting the quality of life of patients with idiopathic Parkinson's disease-a cross-sectional study in an outpatient clinic attendees. Parkinsonism & Related Disorders 11: 465–468.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner